Team game – how the use of single pill combination or hybrid therapy may curb high cardiovascular risk Review article
Article Sidebar
Published:
Dec 31, 2020
Keywords:
hypertension, hypercholesterolemia, treatment, single-pill hybrid drugs
Main Article Content
Abstract
The health effects of both primary or secondary prevention strategies outperform any method used to treat any acute cardiovascular diseases. The paper highlights basic impediments associated with individual implementation of recommended health preserving behaviors and treatments. The most critical barriers limiting possible health benefits of prevention are discussed. The health benefits of the use and popularization among physicians of single pill combination and hybrid therapy are also brought into focus.
Article Details
How to Cite
Waliczek , M., & Rozentryt, P. (2020). Team game – how the use of single pill combination or hybrid therapy may curb high cardiovascular risk. Medycyna Faktow (J EBM), 13(4(49), 476-481. https://doi.org/10.24292/01.MF.0420.14
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Bandosz P, O’Flaherty M, Drygas W et al. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ (Clinical research ed). 2012; 344: d8136.
2. Ford ES, Ajani UA, Croft JB et al. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000. N Engl J Med. 2007; 356(23): 2388-98.
3. Pajak A, Szafraniec K, Polak M et al. Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study. Pol Arch Med Wewn. 2016; 126(9): 642-52.
4. Małyszko J, Mastej M, Banach M et al. Do we know more about hypertension in Poland after the May Measurement Month 2017? Europe. Eur Heart J Suppl. 2019; 21(suppl D): D97-D100.
5. Zdrojewski T, Solnica B, Cybulska B et al. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol. 2016; 74(3): 213-23.
6. Pająk A, Szafraniec K, Polak M et al. Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study. Polskie Archiwum Medycyny Wewnetrznej. 2016; 126(9): 642-52.
7. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019; 41(1): 111-88.
8. Niklas A, Flotyńska A, Puch-Walczak A et al. Prevalence, awareness, treatment and control of hypertension in the adult Polish population – Multi-center National Population Health Examination Surveys – WOBASZ studies. Arch Med Sci. 2018; 14(5): 951-61.
9. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet (London, England). 2005; 365(9455): 217-23.
10. Fuchs FD, Whelton PK. High Blood Pressure and Cardiovascular Disease. Hypertension. 2020; 75(2): 285-92.
11. Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32): 2459-72.
12. Silverman MG, Ference BA, Im K et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016; 316(12): 1289-97.
13. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta- analysis. Lancet (London, England). 2016; 387(10022): 957-67.
14. Ference BA, Yoo W, Alesh I et al. Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease: A Mendelian Randomization Analysis. J Am Coll Cardiol. 2012; 60(25): 2631-9.
15. Ference BA, Bhatt DL, Catapano AL et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019; 322(14): 1381-91.
16. Niklas A, Marcinkowska J, Kozela M et al. Blood pressure and cholesterol control in patients with hypertension and hypercholesterolemia: the results from the Polish multicenter national health survey WOBASZ II. Pol Arch Intern Med. 2019; 129(12): 864-73.
17. Dyrbus K, Gasior M, Desperak P et al. Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes – Data from the TERCET registry with 19,287 patients. Pharmacol Res. 2019; 139: 460-6.
18. Buddhari W, Uerojanaungkul P, Sriratanasathavorn C et al. Low-Density Lipoprotein Cholesterol Target Attainment in Patients Surviving an Acute Coronary Syndrome in Thailand: Results From the Dyslipidaemia International Study (DYSIS) II. Heart Lung Circ. 2020; 29(3): 405-13.
19. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005; 165(10): 1147-52.
20. Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circ Res. 2019; 124(2): 328-50.
21. Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015; 11(1): 1-23.
22. Soran H, France M, Adam S et al. Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance. Atherosclerosis. 2020; 306: 33-40.
23. Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2015; 37(11): 908-16.
24. Gupta A, Thompson D, Whitehouse A et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017; 389(10088): 2473-81.
25. Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019; 124(7): 1124-40.
26. Chowdhury R, Khan H, Heydon E et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013; 34(38): 2940-8.
27. Gupta P, Patel P, Štrauch B et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension. 2017; 69(6): 1113-20.
28. Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin. 2017; 33(10): 1783-7.
29. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018; 39(33): 3021-104.
2. Ford ES, Ajani UA, Croft JB et al. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000. N Engl J Med. 2007; 356(23): 2388-98.
3. Pajak A, Szafraniec K, Polak M et al. Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study. Pol Arch Med Wewn. 2016; 126(9): 642-52.
4. Małyszko J, Mastej M, Banach M et al. Do we know more about hypertension in Poland after the May Measurement Month 2017? Europe. Eur Heart J Suppl. 2019; 21(suppl D): D97-D100.
5. Zdrojewski T, Solnica B, Cybulska B et al. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol. 2016; 74(3): 213-23.
6. Pająk A, Szafraniec K, Polak M et al. Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study. Polskie Archiwum Medycyny Wewnetrznej. 2016; 126(9): 642-52.
7. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019; 41(1): 111-88.
8. Niklas A, Flotyńska A, Puch-Walczak A et al. Prevalence, awareness, treatment and control of hypertension in the adult Polish population – Multi-center National Population Health Examination Surveys – WOBASZ studies. Arch Med Sci. 2018; 14(5): 951-61.
9. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet (London, England). 2005; 365(9455): 217-23.
10. Fuchs FD, Whelton PK. High Blood Pressure and Cardiovascular Disease. Hypertension. 2020; 75(2): 285-92.
11. Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32): 2459-72.
12. Silverman MG, Ference BA, Im K et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016; 316(12): 1289-97.
13. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta- analysis. Lancet (London, England). 2016; 387(10022): 957-67.
14. Ference BA, Yoo W, Alesh I et al. Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease: A Mendelian Randomization Analysis. J Am Coll Cardiol. 2012; 60(25): 2631-9.
15. Ference BA, Bhatt DL, Catapano AL et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019; 322(14): 1381-91.
16. Niklas A, Marcinkowska J, Kozela M et al. Blood pressure and cholesterol control in patients with hypertension and hypercholesterolemia: the results from the Polish multicenter national health survey WOBASZ II. Pol Arch Intern Med. 2019; 129(12): 864-73.
17. Dyrbus K, Gasior M, Desperak P et al. Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes – Data from the TERCET registry with 19,287 patients. Pharmacol Res. 2019; 139: 460-6.
18. Buddhari W, Uerojanaungkul P, Sriratanasathavorn C et al. Low-Density Lipoprotein Cholesterol Target Attainment in Patients Surviving an Acute Coronary Syndrome in Thailand: Results From the Dyslipidaemia International Study (DYSIS) II. Heart Lung Circ. 2020; 29(3): 405-13.
19. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005; 165(10): 1147-52.
20. Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circ Res. 2019; 124(2): 328-50.
21. Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015; 11(1): 1-23.
22. Soran H, France M, Adam S et al. Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance. Atherosclerosis. 2020; 306: 33-40.
23. Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2015; 37(11): 908-16.
24. Gupta A, Thompson D, Whitehouse A et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017; 389(10088): 2473-81.
25. Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019; 124(7): 1124-40.
26. Chowdhury R, Khan H, Heydon E et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013; 34(38): 2940-8.
27. Gupta P, Patel P, Štrauch B et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension. 2017; 69(6): 1113-20.
28. Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin. 2017; 33(10): 1783-7.
29. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018; 39(33): 3021-104.